What question did this study set out to answer?

This study investigates the impact of continuous glucose monitoring (CGM) on management and quality of life in those diagnosed with gestational diabetes.

June 7, 2026

2901-LB: Real-World Use of CGM in Gestational Diabetes Management: A Multisite Clinical Study

Key Points

This study investigates the impact of continuous glucose monitoring (CGM) on management and quality of life in those diagnosed with gestational diabetes.
Participants diagnosed with gestational diabetes were enrolled at three sites.
Used Dexcom G7 CGM for glucose monitoring throughout pregnancy with a standardized education sheet.
Outcomes measured included CGM usage metrics and satisfaction surveys administered postpartum.
50 individuals enrolled, with 93% adherence to CGM use.
88% preferred CGM over self-monitoring blood glucose (SMBG), citing improved quality of life.
Notable nocturnal CGM metrics differences between groups; challenges included alarm fatigue and glucose level worries.

Abstract

Introduction and Objective: A gestational diabetes (GDM) diagnosis is unexpected and brings immediate need for diabetes self-management. This multicenter observational study examined the impact of CGM on individual’s experiences with GDM management. Methods: People diagnosed with GDM were enrolled at 3 sites, a standardized patient education sheet was reviewed and provided and participants were asked to use Dexcom G7 CGM for glucose monitoring for the remainder of pregnancy. GDM was managed by their obstetric clinicians. Outcomes included CGM metrics and satisfaction surveys administered postpartum. Results: 50 individuals (A1 no medication n=18, A2 medication use n=32) were enrolled: BMI 31.0 (IQR 23.3, 36.8), 31 (62%) White, 41 (84%) CGM naive. CGM was worn 93% of days. Significant differences were seen in nocturnal CGM metrics between groups (Table). Satisfaction was high: 88% preferred CGM over SMBG with themes that CGM improved quality of life and provided new information about diabetes. Challenges for some participants included worry about glucose levels, sleep disruption, alarm fatigue and data issues. Conclusion: Individuals with GDM consistently used CGM with results suggesting CGM may improve self-management, quality of life during pregnancy and provide opportunities to optimize therapy for those using medication. Certain themes emerged where pregnant people may benefit from more education regarding CGM to improve their experience and health optimization. Disclosure A.M. Valent: Research Support; Current; Dexcom, Inc. Advisory Panel; Current; MannKind Corporation. Research Support; Current; MannKind Corporation. K. Castorino: Research Support; Current; Abbott, Abbott Diabetes. Research Support; Ended; Altimmune. Research Support; Current; Dexcom, Inc. Speaker's Bureau; Current; Dexcom, Inc. Research Support; Current; Eli Lilly and Company. Advisory Panel; Current; MannKind Corporation. Speaker's Bureau; Current; Insulet Corporation. Consultant; Ended; Sequel Med Tech. J. Layne: Employee; Current; Dexcom, Inc. Y. Xu: Employee; Current; Dexcom, Inc. D. Zabala: Employee; Current; Dexcom, Inc. B. Carrillo: Employee; Current; Dexcom, Inc. Stock/Shareholder; Current; Dexcom, Inc. C. Durnwald: Research Support; Current; Abbott Diabetes. Advisory Panel; Current; Abbott Diabetes. Research Support; Current; Dexcom, Inc., MannKind Corporation.

Mark Helpful

Bookmark

Relay